Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin (2021 - 2025)

InMed Pharmaceuticals' Net Margin history spans 5 years, with the latest figure at 247.29% for Q4 2025.

  • For Q4 2025, Net Margin fell 1566.0% year-over-year to 247.29%; the TTM value through Dec 2025 reached 170.07%, down 645.0%, while the annual FY2025 figure was 165.14%, 180.0% up from the prior year.
  • Net Margin reached 247.29% in Q4 2025 per INM's latest filing, down from 154.17% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 14.56% in Q2 2023 to a low of 1615.6% in Q4 2021.
  • Average Net Margin over 5 years is 457.91%, with a median of 193.09% recorded in 2023.
  • Peak YoY movement for Net Margin: skyrocketed 151431bps in 2023, then crashed -13590bps in 2024.
  • A 5-year view of Net Margin shows it stood at 1615.6% in 2021, then soared by 72bps to 446.61% in 2022, then skyrocketed by 73bps to 119.19% in 2023, then tumbled by -94bps to 231.63% in 2024, then fell by -7bps to 247.29% in 2025.
  • Per Business Quant, the three most recent readings for INM's Net Margin are 247.29% (Q4 2025), 154.17% (Q3 2025), and 137.07% (Q2 2025).